New Global Cardiovascular Procedures Report Reveals Medtech Outlook

MedMarket Diligence has published, “Global Dynamics of Surgical and Interventional Cardiovascular Procedures, 2015-2022.”

See link for report description, sources, table of contents, and list of exhibits. The report may be purchased for download.

The report details the therapeutic procedures that address acute and chronic conditions affecting myocardium and vascular system, with relevant prevalences, incidence rates, separate procedure counts for surgical versus interventional and other key splits of the procedure volume.

Screen Shot 2016-08-12 at 9.48.46 AMThe report offers current assessment and projected procedural dynamics (2015 to 2022) for primary market geographies (e.g., United States, Largest Western European Countries, and Major Asian States) as well as the rest-of-the-world.

Each set of forecasts is accompanied by discussion per condition of the changing clinical practice and technology adoption rates, procedural limitations or drivers competitively, the surgical-interventional balance, and the resulting market outlook for cardio manufacturers.

Excerpts available on request.

Drug-eluting, bare metal and absorbable stents segment growth, 2009 and 2017

stents-by-segmentAngioplasty for the revascularization of blocked coronary arteries gave way in the evolution of clinical practice to the adjunctive use of bare metal coronary stents, but due to a high frequency of restenosis bare metal stents gave way to drug-eluting stents (DESs) in 2003 (J&J/CYPHER, followed in 2004 by Boston Scientific’s TAXUS, and soon followed by DES products from Medtronic, Abbott Vascular and a host of others).  While issues of late stage thrombosis in DESs were a brief setback for their sales in 2005-06, they have only modestly recovered, stimulating the further development of technologies to result in revascularized lumens with a minimum of complications (while also giving bare metal stents a persistent toehold on the coronary stent market). Emerging stent or other anti-restenosis technologies in percutaneous coronary intervention include a range of absorbable stents, as well as drug-eluting balloons.

Needless to say (but we will anyway), the coronary stent market (as well as the broader market for treatment of coronary artery disease, encompassing a variety of coronary artery bypass technologies and procedures) remains a dynamic arena for medtech development.


Drawn from Report #C245:  "Worldwide Coronary Stents Market, 2008-2017."